Histamine H3 receptor antagonist E177 attenuates amnesia induced by dizocilpine without modulation of anxiety-like behaviors in rats by Alachkar, Alaa et al.
© 2019 Alachkar et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Neuropsychiatric Disease and Treatment 2019:15 531–542
Neuropsychiatric Disease and Treatment
This article was published in the following Dove Medical Press journal:
Neuropsychiatric Disease and Treatment
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
531
O r i g i N a l  r e s e a r c h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/NDT.s193125
histamine h3 receptor antagonist e177 
attenuates amnesia induced by dizocilpine without 
modulation of anxiety-like behaviors in rats
alaa alachkar1
Nadia Khan1
Dorota Łażewska2
Katarzyna 
Kieć-Kononowicz2
Bassem sadek1
1Department of Pharmacology and 
Therapeutics, college of Medicine and 
health sciences, United arab emirates 
University, al ain, United arab 
emirates; 2Department of Technology 
and Biotechnology of Drugs, Faculty 
of Pharmacy, Jagiellonian University 
Medical college, Kraków, Poland
Background: Alzheimer disease (AD) is the main cause of dementia in elderly people. The 
potential of histamine H3 receptor (H3R) antagonists as a pharmacological treatment of several 
neuropsychiatric diseases is well established. 
Methods: The novel non-imidazole-based H3R antagonist E177 was screened for its pro-
cognitive effects on the inhibitory avoidance paradigm (IAP) and novel object recognition 
(NOR) task in a dizocilpine (DIZ)-induced model of amnesia in male Wistar rats. Donepezil, 
an acetylcholine esterase inhibitor, was used as the reference drug. 
Results: Acute systemic treatment with E177 (1.25, 2.5, 5, and 10 mg/kg intraperitoneally [i.p.]) 
significantly attenuated the cognitive impairments induced by DIZ in the IAP (all P-values ,0.05, 
n=7), and the protective effect of the most promising dose of E177 (5 mg/kg) was abrogated when 
H3R agonist R-(α)-methylhistamine (RAMH; 10 mg/kg i.p.) was co-administered (P=0.281 for 
DIZ-amnesia group vs DIZ + E177 + RAMH group, n=7). The discrimination index calculated 
for E177 (5 mg/kg, i.p.) showed a significant memory-enhancing effect on DIZ-induced short-
term memory impairment in the NOR task (P,0.05, n=6), with the enhancement nullified when 
animals were co-administered RAMH (10 mg/kg). Moreover, the results revealed that E177 
(5 and 10 mg/kg, i.p.) did not alter the anxiety levels and locomotor activity of animals naïve to 
the open-field test (all P-values .0.05, n=8) or the elevated plus maze test (all P-values .0.05, 
n=6–8), which indicated that the E177-induced enhancement of memory performance in the IAP 
or NOR task was unrelated to changes in emotional response or in spontaneous locomotor activity. 
Conclusion: The observed results suggested a possible contribution of H3Rs in the alteration 
of brain neurotransmitters that accompany neurodegenerative diseases, such as AD.
Keywords: Histamine H3 receptors, antagonist, dizocilpine-induced amnesia, inhibitory avoid-
ance paradigm, novel object recognition, elevated plus maze, open field test, memory, anxiety
Introduction
Dementia is one of the most severe manifestations of cognitive impairment associated with 
elderly people and affects ~50 million patients worldwide.1 The neurodegeneration caused 
by Alzheimer disease (AD) is the most common cause of dementia,2,3 and AD is usually 
considered to be one of the most serious progressive lifelong neurodegenerative brain 
diseases, which is characterized by memory insufficiency, confusion, and other behavioral 
deficits.4,5 The number of people diagnosed with AD is predicted to increase from 36 
million to ~100 million in 40 years.5 The pathophysiology of AD is complicated and has 
not been completely established, despite the existence of numerous hypotheses. AD is 
characterized by complex pathophysiological modifications, including insufficient or dis-
turbed neurotransmitters such as the cholinergic, dopaminergic, adrenergic, glutamatergic, 
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and serotonergic neurotransmitters.6 In addition, extracellular 
b-amyloid plaques, neurofibrillary tangles in the brain, and the 
involvement of oxidative stress in the development of AD have 
been well documented.6 In numerous studies and considering 
the clinically used drugs, the most tested therapeutic targets 
include the following: inhibition of acetylcholinesterase, 
antioxidant activity, inhibition of b-amyloid plaque aggrega-
tion, monoamine oxidase enzyme inhibition, and N-methyl-
d-aspartic acid (NMDA) receptor antagonism.7–9 However, 
despite progress in current therapeutic modalities, there are 
112 unique agents in the current AD treatment pipeline: 26 
agents in 35 Phase III trials, 63 agents in 75 Phase II trials, 
and 23 agents in 25 Phase I trials, indicating that the develop-
ment of novel agents with multiple pharmacological effects is 
a promising strategy in the current search for novel treatment 
options for multifactorial diseases such as AD.10–12 Histamine 
is a neurotransmitter of the central nervous system (CNS),13,14 
and it exerts its physiological actions through interaction 
with four different G-protein-coupled histamine receptors 
(H1–H4R).15–17 H1R and H2R are extensively distributed in 
the CNS, gastrointestinal, reproductive, respiratory, and cardio-
vascular systems, whereas H4R is generally limited to immune 
cells.18 In contrast, histamine H3 receptors (H3Rs) are coupled 
to Gα
i/o
-proteins and are mainly expressed in the CNS presyn-
aptically, where they function as inhibitory auto- and hetero-
receptors16,17,19–25 that modulate the production and release of 
histamine and other neurotransmitters such as dopamine, sero-
tonin, acetylcholine, norepinephrine, and glutamate.19–23,26 Pre-
clinical trials have indicated the promising memory-enhancing 
effects of several H3R antagonists.16,17,25,27,28 Subsequently, 
various H3R antagonists, such as ABT-239 and A-431404, 
were shown to attenuate memory impairments induced by dizo-
cilpine (DIZ) or ketamine in different animal species, and their 
procognitive effect was comparable with standard drugs, such 
as donepezil (DOZ),29 which was suggestive of the potential 
use for H3R antagonists in the treatment of neurodegenerative 
diseases such as AD.17,30–33 Consequently, H3Rs appear to be 
a very attractive target for the design of new H3R antagonists 
suitable for the treatment of many neuropsychiatric diseases, 
including epilepsy, schizophrenia, and AD.17,27,31,34–42 Targeting 
H3Rs is not commonly employed for the treatment of AD, 
despite the previous indications about the memory-enhancing 
effects in neurodegenerative disorders. Hence, the protective 
effect of the non-imidazole-based H3R antagonist E177, 
1-(6-(naphthalen-2-yloxy)hexyl)azepane hydrogen oxalate, 
with high antagonist affinity (K
i
=69.40 nM) and high in vitro 
selectivity,43 was tested in DIZ-induced memory impairments 
in Wistar rats subjected to the inhibitory avoidance paradigm 
(IAP) and novel object recognition (NOR) task (Figure 1). 
In addition, anxiety-like behaviors and locomotor activity of 
E177 on the test animals were assessed by using the elevated 
plus maze (EPM) and open-field test (OFT), as modulation 
of these parameters might confound the observations of the 
cognitive performances of the test rats. Moreover, abrogation 
experiments were conducted using the CNS-penetrant H3R 
agonist R-(α)-methyl-histamine dihydrochloride (RAMH) to 
investigate if the procognitive effects of E177 were related to 
central H3R antagonism.
Materials and methods
animals
Inbred male Wistar rats used in the current study were 
obtained from the central animal facility in UAE University. 
The animals were kept in a specific room with controlled 
temperature and humidity (24°C±2°C and 55%±15%, 
respectively), 12/12 hour light/dark sequence, and free 
access to food and water. All the rats were 6–8 weeks of 
age and weighed 180–220 g. The behavioral experiments 
were performed each day between 09:00 am and 01:00 pm 
by the same investigator in a blinded manner; all procedures 
were performed in accordance with the guidelines of the 
European Communities Council Directive of 24 November 
1986 (86/609/EEC) and approval was obtained from the 
Institutional Animal Ethics Committee in College of Medi-
cine and Health Sciences/United Arab Emirates University 
(A30-13) before the experiments were started. All efforts 
were made to minimize the total number of the animals used 
and their pain.
Drugs
E177 was synthesized by the Department of Technology and 
Biotechnology of Drugs (Jagiellonian University Medical 
College, Kraków, Poland), as previously described.43 
Figure 1 Structure and in vitro affinities of the H3R antagonist E177, 1-(6- 
(naphthalen-2-yloxy)hexyl)azepane, on histamine receptor subtypes.
Notes: a[3h]Nα-methylhistamine binding assay was performed using a cell 
membrane preparation of heK-hH3 cells stably expressing the human H3R (n=3). 
b[3h]histamine binding assay was performed using a cell membrane preparation of 
sf9 cells transiently expressing the human histamine h4r and co-expressed with 
gαi2 and b1γ2 subunits (n=2). 
c[3h]pyrilamine binding assay was performed with 
the cell membrane preparation of chO-hh1r cells stably expressing the human 
H1R (n=2).
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Diazepam (DZP) was produced by Gulf Pharmaceutical 
Industries (Ras Al Khaimah, UAE) and was acquired 
from Dr Ameen Al Amaydah (Department of Emergency 
Medicine, Emirates International Hospital, Al Ain, UAE). 
The histamine H3R agonist RAMH, DIZ, and DOZ were 
obtained from Sigma-Aldrich Co. (St Louis, MO, USA). All 
compounds were dissolved in isotonic saline and adminis-
tered intraperitoneally (i.p.) at a volume of 1 mL/kg. All doses 
of test compounds are expressed in terms of the free base.
in vivo behavioral tests
iaP test
The IAP was examined by using inhibitory avoidance 
apparatus (Step-through Cage, 7550; Ugo Basile, Comerio, 
Italy), as described previously.11,12,44,45 The experiments 
were conducted in accordance with the previously published 
protocols.11,12,33,45–51 The test was conducted over 3 days (two 
consecutive training days, with the test performed on the 
third day). The animal was placed in the white compartment 
in front of the door for a 30-second habituation period at the 
beginning of the first training day, and then the door was 
routinely raised up. Once the animal passed with head and all 
four paws into the black compartment, a foot shock (0.4 mA, 
20 Hz, 8.3 ms) was applied for a duration of 3 seconds. The 
step-through latency (STL) time was calculated (the cut-off 
time was set at 60 seconds) and the animals that did not enter 
the dark compartment within 60 seconds were excluded 
from the experiment. The intensity of the foot shock was 
chosen to minimize pain and reactions, such as jumping and 
screaming, in the examined animals. Directly after the foot 
shock was delivered, the respective animal was returned 
to its home cage and both compartments were cleaned to 
eliminate any olfactory signs. On the second training day 
(24 hours later), the experimental steps were repeated, except 
that the foot shock was not delivered and the cut-off latency 
time was increased to 300 seconds. On both training days, 
the rats received an injection of saline 30–45 minutes before 
starting the experiment, whereas on the test day (24 hours 
later), animals were injected with the test compound DIZ 
(0.1 mg/kg, i.p.) 30–45 minutes before the test. STL time was 
calculated on the test day with a cut-off time of 300 seconds, 
and no foot shock was delivered.
Treatment groups
Ten groups were used in this experiment; each group included 
six to eight animals matched for age and weight. All groups 
were treated with i.p. injections 30–45 minutes before the 
test. The procognitive effect of different doses of the test 
compound E177 was examined through the measurement 
of STL times for each animal in all groups. The rats were 
divided into the following treatment groups: Group 1, in 
which saline was co-injected with saline; Group 2, saline co-
injected with DIZ (0.1 mg/kg); groups 3–6, DIZ co-injected 
with E177 (1.25, 2.5, 5, or 10 mg/kg, respectively); Group 7, 
DIZ co-injected with DOZ (1 mg/kg i.p.); Group 8, DIZ co-
injected with the most promising dose of E177 (5 mg/kg) 
and the H3R agonist RAMH (10 mg/kg) for the abrogation 
study; Group 9, DIZ co-injected with RAMH (10 mg/kg); and 
Group 10, saline co-injected with RAHM (10 mg/kg). Doses 
of all tested compounds were selected based on previously 
conducted experiments for several non-imidazole-based H3R 
antagonists tested in adult male rats (Figures 2 and 3).33,52,53
NOr task
The NOR task was used to assess both the short-term 
memory (STM) and long-term memory (LTM) recogni-
tion in male Wistar rats by using an open square black box 
(50×35×50 cm), as described previously.33,45 The NOR 
task was conducted in the morning between 8:00 am and 
12:00 pm. On the first day, two habituation sessions, sepa-
rated by 1 hour, were conducted; each animal was allowed 
to habituate the box for 3 minutes and was then returned to 
its home cage and the box was cleaned. On the second day, 
the trial consisted of training session T1 and test session T2, 
which were separated by 120 minutes for the STM assessment 
Figure 2 E177 attenuated DIZ-induced memory deficits in the IAP.
Notes: Average STL time measured on the first training day before the delivery of 
foot shock (white columns), and average STL time measured on the test day (black 
columns). Acute systemic administration of E177 at different doses (1.25, 2.5, 5, 
and 10 mg/kg i.p.) or DOZ (1 mg/kg i.p.) 30–45 minutes before the test session. 
#P,0.0001 for average sTl time compared with that in the saline-treated group. 
*P,0.0001 for average sTls compared with the DiZ-treated group. &P,0.0001 
compared with the DOZ-treated group. $P,0.05 compared with the DOZ-treated 
group. The data are expressed as the mean ± SEM (n=7).
Abbreviations: DiZ, dizocilpine; DOZ, donepezil; iaP, inhibitory avoidance 
paradigm; i.p., intraperitoneally; sal, saline; seM, standard error of the mean; sTl, 
step-through latency.
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and by 24 hours for the LTM assessment. In T1, the animals 
were introduced to two identical wooden objects (9×5×9 cm) 
placed in opposite corners of the box (30 cm apart) for 
3 minutes and the time the animal spent exploring each 
object was calculated (exploration of an object was defined 
as touching or snuffing the object; other behavioral observa-
tions, such as turning around or sitting on the object, were not 
considered an experimental behavior). The animals which 
explored the objects for ,10 seconds (one to three animals 
out of the nine animals per group) were excluded from the 
experiment. In T2, an identical familiar object to eliminate 
any olfactory clues and a novel object were introduced to the 
animal for a 3-minute session and the time the animal spent 
exploring the familiar and novel objects was measured. All 
objects and the test arena were cleaned by using 70% ethanol 
after each session. To assess the procognitive effect of our test 
compound E177, DIZ was used to induce amnesia. DIZ and 
E177 (different doses) were dissolved in saline and injected 
i.p. after T1; E177 was injected i.p. 30–45 minutes before 
T2 in the LTM assessment only, and the control groups were 
injected with an equal volume of saline. Doses and treatment 
times were chosen in accordance with previously published 
studies that have reported the memory-enhancing effects of 
H3R antagonists in the NOR task.33,45
Treatment groups
Nine groups, comprising six to eight animals matched for 
weight and age, were used in this experiment. The rats were 
divided into the following treatment groups: Group 1, in 
which saline was co-injected with saline; Group 2, saline 
co-injected with DIZ (0.1 mg/kg); groups 3–5, DIZ co-
injected with E177 (2.5, 5, or 10 mg/kg); Group 6, DIZ 
co-injected with DOZ (1 mg/kg); Group 7, DIZ co-injected 
with E177 (5 mg/kg) and H3R agonist RAMH (10 mg/kg) 
for the abrogation study; Group 8, saline co-injected with 
RAMH (10 mg/kg); and Group 9, DIZ co-injected with 
RAMH (10 mg/kg). The systemic administration of E177 
and RAMH was repeated 30–45 minutes before T2 for the 
LTM assessment. The discrimination index (DI) was calcu-
lated from the variables N–F/N+F (where N is the time the 
rat spent exploring the novel object and F is the time the 
rat spent exploring the familiar object in T2), as shown in 
Figure 4A and B.
ePM test
To estimate the anxiety-like behaviors in male Wistar rats, 
the EPM test was used as previously described.45,54 The EPM 
apparatus consisted of a central part (8×8 cm), two open 
arms (30×8 cm), and two closed arms (30×8 cm) bordered 
by non-transparent walls (height: 30 cm) and illuminated 
with four 60 V light-emitting diodes (LEDs). The test was 
conducted in the morning, between 08:00 am and 12:00 pm; 
each animal was placed in the center of the maze (50 cm 
above the floor), facing one of the open arms for a duration 
of 5 minutes, and the number of entries to both open and 
closed arms (when the rat entered with head and forepaws) 
as well as the time spent in the open and closed arms were 
measured manually. The arms and walls of the apparatus 
were cleaned with 70% ethanol between each animal’s use 
of the apparatus to remove any confounding olfactory cues. 
The total number of closed arm entries was considered to be 
an indication of locomotor activity.
Treatment groups
Four groups, comprising six to eight animals matched for 
weight and age, were used in this experiment. All the animals 
received i.p. injections 30–45 minutes before the test to assess 
the alternation effects of E177 on anxiety-like parameters and 
locomotor activity (Figure 5). The animals were divided into 
the following treatment groups: Group 1, in which saline was 
co-injected with saline; groups 2 and 3: E177 (5 or 10 mg/kg, 
respectively); and Group 4, DZP (10 mg/kg).
Figure 3 raMh reversed e177-induced memory enhancement of the DiZ-induced 
deficit in the IAP.
Notes: Average of STL time measured on the first training day before the delivery 
of foot shock (white columns), and average of the STL time measured on the 
test day (black columns). Acute systemic administration of E177 (5 mg/kg, i.p.), 
RAMH, and E177 (5 mg/kg) + RAMH (10 mg/kg) for 15–20 minutes (for RAMH) 
or 30–45 minutes (for H3R antagonist E177) before the test session. #P,0.001 
average sTls compared with the saline-treated group. *P,0.001 for the average 
sTl time compared with that in the DiZ-treated group. The data are expressed as 
the mean ± SEM (n=7).
Abbreviations: DiZ, dizocilpine; iaP, inhibitory avoidance paradigm; i.p., 
intraperitoneally; raMh, R-(α)-methyl-histamine dihydrochloride; SAL, saline; 
seM, standard error of the mean; sTl, step-through latency.
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Open-field test
The locomotor activity was assessed by using a home-made 
OFT, as previously described.11,12,44 The test arena (floor, 
56×56 cm of black polyvinyl chloride; walls, 56 cm high 
of black Formica) was open to above and illuminated with 
four 60 V LEDs. The floor of the box was divided into 
32 equal squares, each 14 cm in diameter. The four squares 
in the middle were considered to be the “center” of the 
field. On the test day, rats were allowed to move freely in 
the box for 30 minutes (habituation time) and were then 
subsequently returned to their home cages, and the box was 
cleaned. Thirty minutes later, the rats received i.p. injections 
of the test compound, 30–45 minutes before the test was 
conducted. For the test session, the animals were transferred 
to the arena only by their tails and placed in the center where 
they were allowed to move freely for 3 minutes. During this 
time, animal activity was recorded by a digital camera placed 
above the arena, and video recordings were later utilized for 
assessment. As illustrated above, different parameters were 
measured, such as the total distance traveled, the time spent in 
the central arena as well as in the periphery, and the number 
of grooming incidents during the 3-minute test session, 
through analysis of the video recordings in accordance with 
previously published methods.32,44 When evaluating the 
Figure 4 E177 mitigated DIZ-induced short-term deficits in NOR paradigm.
Notes: E177 (2.5, 5, or 10 mg/kg, i.p.) or DOZ (1 mg/kg, i.p.) was injected after T1 (training session) with DIZ (0.1 mg/kg, i.p.). The T2 (test session) was conducted 
120 minutes (STM, A) or 24 hours (LTM, B) after T1 (training session). The results are expressed as DIs for the time spent exploring both objects (familiar and novel). 
#P,0.0001 compared with the sal-treated group. *P,0.05 compared with the DiZ-treated group. ***P,0.0001 compared with the DiZ-treated group. $P,0.05 compared 
with the E177 (5 mg)-treated group. The data are expressed as the mean ± SEM (n=6).
Abbreviations: Dis, discrimination indices; DiZ, dizocilpine; DOZ, donepezil; i.p., intraperitoneally; lTM, long-term memory; NOr, novel object recognition; raMh, R-(α)-
methyl-histamine dihydrochloride; sal, saline; seM, standard error of the mean; sTM, short-term memory.
Figure 5 e177 failed to alter anxiety-like behavior or locomotion in the ePM test.
Notes: Effect of E177 (5 or 10 mg/kg, i.p.) and DZP (10 mg/kg, i.p.) injections on the percentage of time spent in open arms (A), total number of open arm entries (B), and 
total number of closed arms entries (C). *P,0.05 for the value of the DZP-treated group compared with the saline-, E177 (5 mg)-, or E177 (10 mg)-treated groups. The data 
are expressed as the mean ± SEM (n=6).
Abbreviations: DZP, diazepam; ePM, elevated plus maze; i.p., intraperitoneally; sal, saline; seM, standard error of the mean; Oa, open arms; ca, closed arms.
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results, longer time spent in the center indicated lower levels 
of anxiety-like behaviors (Table 2).
Treatment groups
Four groups, comprising six to eight animals matched for 
weight and age, were used in this experiment. All the animals 
received i.p. injection 30–45 minutes before the test to assess 
the effects of E177 on anxiety-like parameters and locomotor 
activity. The animals were divided into the following treat-
ment groups: Group 1, in which saline was co-injected with 
saline; groups 2 and 3, E177 (5 and 10 mg/kg, respectively); 
and Group 4, DOZ (1 mg/kg).
statistical analyses
The data were analyzed for normality through assessment of 
the sample distribution or skewness (-1.3 to +1.3 was con-
sidered to be normally distributed) and the homogeneity of 
variance by using Levene’s test. After the results had passed 
the tests for normality, they were analyzed where applicable 
using one- or two-way ANOVA followed by Tukey’s post 
hoc test. For statistical comparisons, the software package 
SPSS 25.0 (IBM Middle East, Dubai, UAE) was used. 
The results are expressed as the mean and standard error of 
the mean (SEM). P-values ,0.05 were considered to indicate 
statistical significance.
Results
e177 and DOZ attenuated the DiZ-
induced memory impairments in the iaP
The procognitive effects of E177 (1.25, 2.5, 5, and 
10 mg/kg) and the standard drug DOZ (1 mg/kg) on DIZ-
induced memory deficits in IAP in adult male rats are 
shown in Figure 2. Following statistical analysis of STL 
times, acute systemic administration of E177 and DOZ 
(1 mg/kg) 30–45 minutes before the test conferred signifi-
cant memory-enhancing effects (F
(4,49)
=66.81, P,0.0001; 
Figure 2). Post hoc analyses by the Tukey’s test revealed 
that DIZ (0.1 mg/kg) treatment significantly reduced STL 
time compared with the saline-treated group (mean dif-
ference =260.14, P,0.0001). Moreover, all four doses of 
E177 (1.25, 2.5, 5, and 10 mg/kg) resulted in a significant 
enhancement of STL times compared with the DIZ-induced 
amnesia group (all P-values ,0.0001). Furthermore, E177 
(1.25 and 2.5 mg/kg) exhibited procognitive effects on STL 
time, which were comparable with the reference drug DOZ 
(1 mg/kg), with P-values of 1.00 and 0.05, respectively 
(Figure 2). However, higher doses of E177 (5 and 10 mg/kg) 
provided significantly stronger memory-enhancing effects 
than DOZ (1 mg/kg), with P-values of ,0.0001 and ,0.05, 
respectively (Figure 2). Notably, no significant increase was 
observed between 5 and 10 mg/kg E177 (P=0.94; Figure 2).
h3r agonist raMh reversed memory 
improvement provided by e177 in rats 
with DiZ-induced impairments in the iaP
In this experiment, animals were co-injected with the most 
promising dose of E177 (5 mg/kg) 30–45 minutes before 
the test and with RAMH (10 mg/kg) 20 minutes before the 
test (Figure 3). Statistical analysis and pairwise compari-
sons indicated that E177 (5 mg/kg) improved STL times in 
comparison with the DIZ-induced amnesia group (mean 
difference =260.14, P,0.0001; Figure 3). E177 (5 mg) 
treatment resulted in improved STL times, which were 
reversed following acute systemic co-administration with 
RAMH (mean difference =13.29, P=0.88, DIZ-induced 
amnesia group vs DIZ + E177 + RAMH group; Figure 3). 
Notably, acute systemic administration of DIZ (0.1 mg)-
treated or saline-treated animals with RAMH (10 mg/kg) 
failed to significantly alter the STL times observed in each 
group (mean difference =3.57 [P=1.00] and 23.34 [P=0.40], 
respectively; Figure 3).
h3r antagonist e177 and DOZ 
counteracted DIZ-induced STM deficits 
in the NOr task
The observed DIs for E177 (5 mg/kg) and DOZ (1 mg/kg) 
in DIZ-induced STM deficits in the NOR task are shown 
in Figure 4A. The results showed that post-T1, acute 
systemic administration of E177 and DOZ significantly 
counteracted the time spent exploring the objects in the 
T2 session (F
(8,54)
=17.58, P,0.001; Figure 4A). More-
over, post hoc analyses of the DI results showed that DIZ 
(0.1 mg/kg i.p.) significantly impaired the novel object 
memory in T2 when compared with the saline-treated 
group (mean difference =0.42, P,0.0001). However, DOZ 
(1 mg/kg i.p.) and E177 (5 and 10 mg/kg i.p.) significantly 
counteracted the STM impairment induced by DIZ (mean 
differences of 0.44 [P,0.0001], 0.21 [P,0.05], and 0.20 
[P,0.05], respectively; Figure 4A). In contrast, lower 
doses of E177 (2.5 mg/kg) failed to reverse the DIZ-induced 
memory impairment (mean difference =0.04, P=0.99; Figure 
4A). Moreover, no significant difference in the protective 
effects was observed for either dose of E177, namely, 5 and 
10 mg/kg (mean difference =0.005, P=1.00). Unexpectedly, 
and as compared with the DIZ-treated group, abrogation of 
 
N
eu
ro
ps
yc
hi
at
ric
 D
is
ea
se
 a
nd
 T
re
at
m
en
t d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
18
5.
17
2.
86
.1
91
 o
n 
06
-M
ay
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2019:15 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
537
alachkar et al
the protective effect of the H3R antagonist E177 (5 mg/kg) 
was observed when animals were co-injected i.p. with 
10 mg/kg of the H3R agonist RAMH (mean difference =0.19, 
P=0.075). In addition, statistical analyses revealed that 
RAMH (10 mg/kg i.p.) alone did not modulate STM in T2 
compared with the saline- and DIZ-treated groups (mean 
differences of 0.067 [P=0.969] and 0.052 [P=0.994], respec-
tively; Figure 4A). Importantly, the time spent exploring 
both objects through T1 and T2 was not significantly dif-
ferent in the DIZ-treated group and the saline-treated group 
(Table 1). This is essential to confirm the elimination of any 
confounding factors, such as the failure of DIZ post-training 
treatment in T1 to alter the spontaneous locomotion and/or 
motivations of tested animals.
e177 failed to counteract DiZ-induced 
LTM deficits in the NOR task
Figure 4B shows the effects observed for E177 (2.5, 5, and 
10 mg/kg) and DOZ (1 mg/kg i.p.) on DIZ-induced LTM in 
the NOR task. The results demonstrated the significant modu-
latory effects of E177 and DOZ on the time spent exploring 
both objects in T2 (F
(8,54)
=5.071, P,0.0001), when injected 
in the post-training session T1 and 30–45 minutes before T2 
on the following day (Figure 4B). Post hoc analyses of the 
DIs indicated that DIZ (0.1 mg/kg i.p.) significantly reduced 
the DI in T2 compared with the saline-treated group (mean 
difference =0.33, P,0.05; Figure 4B). Acute systemic pre-
treatment with DOZ (1 mg/kg i.p.) significantly improved the 
DI between the two objects (mean difference =0.07, P,0.05) 
compared with the DIZ-treated group. However, E177 (2.5, 
5, and 10 mg/kg) failed to significantly attenuate the DI 
between the two objects compared with the DIZ-treated 
group (mean differences of 0.3 [P=1.00], 0.15 [P=0.51], and 
0.09 [P=0.93], respectively; Figure 4B).
e177 did not alter animal performance 
in the ePM paradigm
The observed results of the anxiety-like behaviors after acute 
systemic administration of E177 (5 and 10 mg/kg) and DZP 
(10 mg/kg) are shown in Figure 5. As shown by post hoc 
analyses, no significant alteration was observed in the time 
spent in the open arms for the E177 (5 and 10 mg)-treated 
groups compared with the saline-treated group (F
(1,10)
=0.050 
[P=0.828] and 0.107 [P=0.750], respectively; Figure 5A 
and B). In addition, the statistical analyses indicated no 
change in the total number of entries into the open arms for 
E177 (5 and 10 mg/kg), with F
(1,10)
 values of 0.027 (P=0.872) 
and 0.008 (P=0.929), respectively, compared with the saline-
treated group (Figure 5A and B). In contrast, both the percent-
age of time spent in the open arms and the total number of 
entries into the open arms were significantly altered following 
DZP (10 mg/kg) treatment compared with the saline-treated 
group (F
(1,10)
=8.605 [P,0.05] and F
(1,10)
=6.139 [P,0.05], 
respectively; Figure 5A and B). Notably, no significant 
change was shown in the total number of entries into the 
closed arms after acute systemic administration of E177 
(5 and 10 mg/kg) or DZP (10 mg/kg), with F
(1,10)
 values of 
0.005 (P=0.944), 0.593 (P=0.459), and 0.004 (P=0.950), 
respectively (Figure 5C).
e177 did not modify anxiety-like 
behaviors and locomotor activity in OFT
To simultaneously exclude the possible intrinsic deficit of 
spontaneous locomotor activity, the effect of E177 (5 and 
Table 1 effects of e177 on dizocilpine-induced total exploratory time spent with both objects during the training and test sessions 
in the NOr paradigm
Groups n Time exploring objects (seconds)
Training 
session STM
Test session 
STM
Training 
session LTM
Test session 
LTM
saline 6 36.50±2.69 40.33±2.75 36.67±2.93 38.17±3.86
DiZ + saline 6 37.00±2.49 33.75±3.09 37.63±2.30 38.14±6.47
DiZ + E177 (2.5 mg/kg) 6 38.50±2.37 40.08±1.57 36.83±1.99 36.17±1.66
DiZ + E177 (5 mg/kg) 6 38.67±2.52 38.63±2.48 37.67±2.55 33.17±2.19
DiZ + E177 (10 mg/kg) 6 38.17±2.17 36.08±0.72 37.50±2.63 37.83±3.16
DiZ + DOZ (1 mg/kg) 6 37.33±4.41 37.75±2.17 38.50±1.16 38.29±2.29
DiZ + E177 (5 mg/kg) + RAMH (10 mg/kg) 6 39.17±1.34 39.25±2.39 39.88±2.57 37.96±1.56
DiZ + RAMH (10 mg/kg) 6 38.00±4.22 37.42±1.86 39.33±1.56 37.46±1.30
saline + RAMH (10 mg/kg) 6 38.25±2.88 37.42±2.20 38.75±2.14 37.83±4.29
Notes: No significant changes in total exploratory times were observed between the treatment groups. The data are expressed as the mean ± SEM (n=6).
Abbreviations: DiZ, dizocilpine; DOZ, donepezil; lTM, long-term memory; NOr, novel object recognition; raMh, R-(α)-methyl-histamine dihydrochloride; SEM, standard 
error of the mean; sTM, short-term memory.
 
N
eu
ro
ps
yc
hi
at
ric
 D
is
ea
se
 a
nd
 T
re
at
m
en
t d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
18
5.
17
2.
86
.1
91
 o
n 
06
-M
ay
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2019:15submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
538
alachkar et al
10 mg/kg, i.p.) was assessed in an OFT (Table 2). Locomotor 
activity was evaluated by the time spent in the center and 
periphery of the arena. In addition, the total time spent for 
locomotion, total distance traveled, and occurrences of 
rearing and grooming were assessed. One-way ANOVA 
showed that E177 (5 and 10 mg/kg) and DOZ (1 mg/kg) had 
no effect on the time spent in the center and periphery and 
on the total time spent for locomotion compared with the 
saline-treated group, with F
(1,10)
 values of 0.385 (P=0.549), 
0.059 (P=0.813), and 0.023 (P=0.883), respectively, for E177 
(5 mg/kg), F
(1,11)
 values of 0.017 (P=0.899), 0.018 (P=0.895), 
and 0.011 (P=0.920), respectively, for E177 (10 mg/kg), 
and F
(1,10)
 values of 0.294 (P=0.599), 0.527 (P=0.484), and 
1.228 (P=0.294), respectively, for DOZ (1 mg), as shown in 
Table 2. Statistical analyses of data describing the total dis-
tance traveled, the number of rearing events, and the number 
of grooming events for E177 at doses of 5 and 10 mg/kg gave 
essentially the same results (all P-values .0.05; Table 2). 
Similarly, animals that had acute systemic administration 
of DOZ (1 mg/kg) or E177 (5 and 10 mg/kg, i.p.) did not 
have a significantly different number of grooming events 
compared with the saline-treated group, with F
(1,10)
 values 
of 2.76 (P=0.128), 0.43 (P=0.527), and 0.05 (P=0.828), 
respectively (Table 2).
Discussion
The results of this study clearly showed that the H3R antago-
nist E177 could dose-dependently (2.5, 5, and 10 mg/kg, i.p.) 
mitigate DIZ-induced cognitive impairments in an inhibitory 
paradigm in rats via the appropriate modulation of brain 
histaminergic neurotransmission (Figure 2). DIZ is well rec-
ognized as an NMDA receptor antagonist, and the significant 
involvement of NMDA receptors has been confirmed in both 
consolidation and retrieval processes.12,55–57 Accordingly, it 
is probable that E177 attenuated the memory impairment 
induced by DIZ, as a consequence of antagonizing the 
histamine H3 autoreceptors, with the resultant increase in 
the release of brain histamine, which is thought to interact 
with and activate NMDA receptors. The latter conclusions 
were supported by previous publications, which indicated 
that histamine enhanced the neurotransmission mediated by 
NMDA receptors in cultured hippocampal cells and signified 
that brain histamine and NMDA receptor interaction might 
help to ameliorate the memory deficits induced by DIZ in 
IAP. E177 also significantly and dose-dependently attenu-
ated the memory deficits induced by DIZ, as E177 at 5 and 
10 mg/kg doses significantly prolonged STL time compared 
to that with lower doses (1.25 and 2.5 mg/kg; Figure 2). 
As no additionally significant increase in the protective effect 
was detected with an increase in the dose of E177 from 5 to 
10 mg/kg, E177 (5 mg/kg) was considered the optimum 
dose to confer memory-enhancing effects (Figure 2). The 
subsequent observations for the dose-dependent effects 
provided by E177 also agreed with those reported for 
several H3R antagonists in previous preclinical studies in 
animals.33,46,50,53,58,59 Notably, the protective effects of E177 
(5 and 10 mg/kg) were comparable with the protective effect 
achieved with the standard drug DOZ, an acetylcholine ester-
ase inhibitor clinically used for memory-enhancing effects 
(Figure 2). Moreover, the memory-enhancing effect of E177 
(5 mg) was abrogated when rodents were co-administered 
with the CNS-penetrant H3R agonist RAMH, which demon-
strated that H3Rs antagonism was a considerable contributor 
to the central neurotransmission functions linked with 
retrieval processes in the tested animals (Figure 3).
In rodents, the NOR task is a benchmark for the evalu-
ation of recognition memory.60 Usually, there is no com-
pensation or penalty for the animals in NOR test; the 
task assesses the animal’s native propensity to explore 
their environment as it is dependent on the animal’s innate 
behavior.61–64 In the current study, the most promising dose 
of E177 in the IAP (5 and 10 mg/kg) significantly enhanced 
the time spent exploring the novel object over that exploring 
the familiar object (Figure 4A). These results agreed with 
Table 2 effects of acute systemic administration of e177 on anxiety levels and locomotor activity in the OFT
Groups Time for 
locomotion 
(seconds)
Distance 
traveled (cm)
Time in center 
(seconds)
Time in 
periphery 
(seconds)
No. of rearing 
events
No. of grooming 
events
saline 99.67±6.47 1,003.33±51.34 1.67±0.19 78.67±6.40 18.17±2.41 2.00±0.58
E177 (5 mg/kg) 98.33±4.78 1,085.67±33.95 1.83±0.15 76.67±3.93 16.17±1.79 1.50±0.39
E177 (10 mg/kg) 100.86±8.16 999.86±52.44 1.71±0.26 77.14±7.87 15.14±2.54 1.86±0.31
DOZ (1 mg/kg) 109.83±5.31 1,022.67±44.65 1.50±0.20 71.33±6.63 16.67±2.55 0.67±0.45
Notes: E177 (5 and 10 mg/kg, i.p.) failed to alter time spent in the center arena, time spent in the periphery, total time spent for locomotion, total distance traveled, 
occurrence of rearing, and incidence of grooming. The data are expressed as the mean ± SEM (n=6–7).
Abbreviations: DOZ, donepezil; i.p., intraperitoneally; OFT, open-field test; SEM, standard error of the mean.
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observations in earlier preclinical studies in which various 
imidazole-based H3R antagonists, such as thioperamide and 
clobenpropit,65 and non-imidazole-based H3R antagonists, 
such as pitolisant, GSK189254, SAR110894, ABT-239, and 
E159,53,66–69 attenuated the memory impairment induced by 
DIZ and scopolamine in the NOR task in a variety of animal 
species. In the current study, the H3R antagonist E177 appre-
ciably counteracted the STM impairment associated with 
DIZ treatment, and the observed protective effect of E177 
was completely reversed when the H3R agonist RAMH was 
co-injected (Figure 4A; Table 1). The previous observa-
tion followed earlier experimental results in which RAMH 
abolished the procognitive effect provided by ciproxifan, an 
imidazole-based H3R antagonist,70 and by DL77 as well as 
E159, the non-imidazole-based H3R antagonists, in rats in 
the NOR task.33,53 In contrast, acute systemic administra-
tion of E177 (2.5, 5, and 10 mg/kg) failed to counteract 
deficits in LTM (E177 injected in the post-training ses-
sion T1 and 30–45 minutes before the test session T2), as 
shown in Figure 4B and Table 1. The latter results agreed 
with previous studies in which the non-imidazole-based 
H3R antagonist E159 did not improve LTM in the NOR 
task in rodents with DIZ-induced memory deficits.53 The 
obtained results in NOR indicated that the modulation of 
brain histamine through H3Rs is particularly involved in the 
neuronal circuits responsible for the E177-provided STM-
enhancing effects, but not in the LTM-enhancing effects 
(Figure 4A and B).
The EPM paradigm is frequently used to investigate 
emotionally related behaviors in rodents.71 The EPM test 
depends on the natural tendency of the animals to prefer 
closed areas over opened areas (anxiety-like evaluation), 
and the number and/or percentage of closed arm entries 
usually provides information on whether the respective test 
compound alters the locomotion of tested animals, to exclude 
any confounding factors in experimental behaviors observed 
in EPM test.45,72–74 E177, administered at a dose of 5 mg/kg 
(the most promising dose in the IAP and NOR tasks), did 
not alter the number of open arm entries for rats in the EPM 
test, indicating that the anxiety-like levels of the tested rats 
were not altered by the effects of E177 on locomotor activity 
(Figure 5A–C). Moreover, E177 (5 mg/kg) altered neither the 
number of closed arm entries in EPM (Figure 5A–C) nor the 
distance traveled, the time spent in the central arena as well 
as in the periphery, and the number of rearing and grooming 
events during a 3-minute test in the OFT (Table 2). Similarly, 
DOZ and E177 did not modulate the number of grooming 
events, which indicated that neither DOZ nor E177 affected 
decision-making behavior, as the incidence of grooming is 
believed to reflect the ability of tested rodents in making 
decisions related to anxiety-like behaviors.75 Therefore, 
the observed enhanced memory performance provided by 
the H3R antagonist E177 in IAP, as well as NOR, was not 
confounded by the altered emotional responses or modified 
spontaneous locomotion, which signified that acute systemic 
administration of E177 (5 mg/kg, i.p.) provided memory-
enhancing effects in the IAP and NOR paradigms owing to 
its capability to improve the learning tasks practiced in the 
training sessions of both memory test models, namely, the 
IAP and NOR tasks.
Conclusion
The novel non-imidazole-based H3R antagonist E177 
counteracted memory impairments induced by DIZ in the 
IAP and NOR tasks in adult male rats without modulation 
of anxiety-like behaviors or locomotion, signifying the 
potential of H3R antagonists as drugs for the treatment of 
several neurodegenerative diseases, including AD. Never-
theless, more preclinical memory-related behavioral experi-
ments in different rodents and other species are required to 
clarify the accurate mechanisms underlying the memory-
improving effects of H3R antagonists and to understand 
their prospective utilization in future therapeutic treatment 
of neurodegenerative diseases. Moreover, consideration 
of the newly developed multi-targeting ligands combining 
pharmacophoric elements of enzymes, such as cholinesterase 
and/or monoamine oxidase, transporters, such as selective 
serotonin reuptake inhibitors, or other disease-modifying 
elements with H3R antagonism may yield improvements in 
preclinical trends in several models of neurodegenerative 
diseases, such as AD in rodents.76,77
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